REG - RTW Biotech Opp. - Notice of 2025 Annual Results & Webinar

RTW Biotech OpportunitiesAnnouncement

16/03/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260316:nRSP6542Wa&default-theme=true

RNS Number : 6542W  RTW Biotech Opportunities Ltd  16 March 2026

LEI: 549300Q7EXQQH6KF7Z84

16 March 2026

RTW Biotech Opportunities Ltd

Notice of 2025 Annual Results & Webinar

RTW Biotech Opportunities Ltd, the London Stock Exchange-listed investment
company focused on identifying transformative assets with high growth
potential across the life sciences sector, is pleased to share that its Annual
Results for the year ended 31 December 2025 will be published on Monday, 30
March 2026.

 

At 10:00 BST on that same day, RTW Investments' Chief Investment
Officer, Rod Wong, and Senior Director of Business & Corporate
Development, Oliver Kenyon, will host a webinar and Q&A via Investor Meet
Company. The webinar is open to all existing and potential shareholders.
Questions can be submitted via your Investor Meet Company dashboard up until
29 March 2026, or to biotechopportunities@rtwfunds.com
(mailto:biotechopportunities@rtwfunds.com) or at any time during the
presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet RTW
Biotech Opportunities Ltd via:
https://www.investormeetcompany.com/rtw-biotech-opportunities-ltd/register-investor
(https://url.us.m.mimecastprotect.com/s/qxZLC0R73guJNyqBHOtlI9zmXc?domain=d31v2n04.eu1.hs-sales-engage.com)

 

Investors who already follow RTW Bio on the Investor Meet Company platform
will automatically be invited.

 

 

 

Enquiries:

 RTW Investments, LP - Investment Manager  +44 (0)20 7959 6362

 Oliver Kenyon                             biotechopportunities@rtwfunds.com

 Krisha McCune (Investor Relations)

 Cadarn Capital - PR & IR Partner

 Lucy Clark (PR)                           +44 (0)7984 184 461 / lucy@cadarncapital.com

 David Harris (Distribution)               +44 (0)7368 883 211 / david@cadarncapital.com

 Deutsche Numis - Joint Corporate Broker   +44 (0)20 7260 1000

 Nathan Brown

 George Shiel

 Duncan Monteith

 BofA Securities - Joint Corporate Broker  +44 (0)20 7628 1000

 Edward Peel

 Alex Penney

 Altum (Guernsey) Limited                  +44 (0)1481 703 100

 Joanna Duquemin Nicolle

 Sadie Morrison

 

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on
identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwbio.com
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/) for more
information.

 

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking
statements, as well as those included in any related materials, are subject to
risks, uncertainties and assumptions about the Company and/or its underlying
investments, including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use of financing
proceeds and future capital expenditures and acquisitions. In light of these
risks, uncertainties and assumptions, the events in the forward-looking
statements may not occur.

The information contained in this announcement is given at the date of its
publication (unless otherwise marked). No reliance may be placed for any
purpose whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or fairness.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORDXLFFQXLBBBZ



            Copyright 2019 Regulatory News Service, all rights reserved